去甲肾上腺素通过SIRT3/HO-1轴介导的铁死亡加重LPS诱导的心肌病
该研究在成年小鼠和H9c2细胞中联合暴露于LPS与去甲肾上腺素,验证两者对心肌损伤的协同作用。结果显示常规剂量去甲肾上腺素长期使用加重LPS诱导的心肌病,伴随铁死亡改变(亚铁、活性氧、线粒体皱缩、脂质过氧化及HO-1表达)。抑制铁死亡、过表达SIRT3或用锌原卟啉抑制HO-1均可减轻心肌细胞死亡与铁死亡。作者认为长期使用去甲肾上腺素可通过SIRT3/HO-1轴介导的铁死亡进一步加重LPS诱导的心肌病。
要点
- 成年小鼠与H9c2细胞中,常规剂量去甲肾上腺素长期使用加重LPS诱导的心肌病。
- LPS与去甲肾上腺素协同作用伴随铁死亡改变:亚铁、活性氧、线粒体皱缩、脂质过氧化及HO-1表达。
- 抑制铁死亡可减轻LPS与去甲肾上腺素诱导的心肌细胞死亡和心肌病。
- 过表达SIRT3减轻去甲肾上腺素+LPS处理的心肌细胞死亡,伴铁死亡与HO-1水平减弱。
- 锌原卟啉(ZnPP)抑制HO-1也减轻去甲肾上腺素与LPS处理心肌细胞的铁死亡。
适用人群与场景
- 成年小鼠与H9c2细胞,暴露于LPS和去甲肾上腺素。
研究设计与关键结果
- 研究类型为动物实验与体外细胞实验,对象为成年小鼠和H9c2细胞,干预为LPS与去甲肾上腺素暴露。
- 常规剂量去甲肾上腺素长期使用加重LPS诱导的心肌病,并伴随铁死亡改变(亚铁、活性氧、线粒体皱缩、脂质过氧化和HO-1表达)。
- 抑制铁死亡可抑制LPS与去甲肾上腺素诱导的心肌细胞死亡和心肌病。
- 过表达SIRT3减轻去甲肾上腺素+LPS处理的心肌细胞死亡,伴铁死亡和HO-1水平减弱。
- 锌原卟啉(ZnPP)抑制HO-1可减轻去甲肾上腺素与LPS处理心肌细胞的铁死亡。
证据类型、等级与局限
- 证据类型:动物实验与体外细胞实验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为长期使用去甲肾上腺素可通过SIRT3/HO-1轴介导的铁死亡进一步加重LPS诱导的心肌病。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Norepinephrine (NE) is a first-line vasopressor for patients with septic shock, and its overuse can lead to "catecholamine adverse effects", including cardiovascular diseases. Lipopolysaccharide (LPS)-induced cardiomyopathy is one of the leading causes of mortality in septic patients. Previous studies have revealed that catecholamine can accentuate LPS-induced cardiomyopathy, but the underlying mechanisms remain elusive.
METHODS: Adult mice and H9c2 cells were exposed to LPS and NE. Structural changes, cardiac function and LDH assays were measured to verify the synergistic effects of LPS and NE in vivo and in vitro. Inhibitors of ferroptosis, heme oxygenase-1 (HO-1) and an activator of SIRT3 were used to reverse the synergistic effects. 4-hydroxynonenal (4-HNE)/MDA assays, immunofluorescence, transmission electron microscopy (TEM) and western blotting were used to measure ferroptosis in this study.
RESULTS: In our study, conventional dosage of NE exacerbated LPS-induced cardiomyopathy in long term, followed by ferroptotic alternations of ferrous iron, reactive oxygen species (ROS), mitochondria shrinkage, lipid peroxidation and HO-1 expression. In addition, inhibition of ferroptosis suppressed cardiomyocyte death and cardiomyopathy induced by LPS and NE, indicating the critical contribution of ferroptosis to cardiac injury via the synergistic effects of NE and LPS. Our recent study identified SIRT3 as a therapeutic target for cardiac ferroptosis. In line with this, overexpression of SIRT3 alleviated the death of cardiomyocytes treated with NE + LPS, accompanied by attenuated ferroptosis and HO-1 level. Moreover, the suppression of HO-1 by zinc protoporphyrin (ZnPP) also attenuated ferroptosis in cardiomyocytes treated with NE and LPS.
CONCLUSION: These data strongly indicate that long-term use of NE can further develop LPS-induced cardiomyopathy via SIRT3/HO-1 axis-mediated ferroptosis.
参考来源
- Ma D, Fang W, Cai L, et al. Norepinephrine exacerbates LPS-induced cardiomyopathy via SIRT3/HO-1 axis-mediated ferroptosis. Crit Care. 2025. PMID: 40804419. doi:10.1186/s13054-025-05602-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。